Cargando...
Development and characterization of an anti-rituximab monoclonal antibody panel
During the development of monoclonal antibodies (mAbs) and other therapeutic proteins, immunogenicity, in particular the induction of anti-drug antibodies (ADAs), is an important concern, and thus immunogenicity assessment is a requirement for their approval. Establishment of appropriate methods for...
Gardado en:
| Publicado en: | MAbs |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Taylor & Francis
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5916554/ https://ncbi.nlm.nih.gov/pubmed/29309213 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2018.1424610 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|